Merck KGaA's combined life science business to be headed by Udit Batra following acquisition

14 April 2015

Germany’s Merck KGaA (MRK: DE) has appointed Udit Batra to head the combined life science business following the pending acquisition of US life science company Sigma-Aldrich.

Dr Batra is currently chief executive and president of Merck Millipore, and has been appointed to lead the combined life science business of Merck Millipore and Sigma-Aldrich once this acquisition has been successfully completed. The $17 billion transaction is subject to customary closing conditions and regulatory approvals, which the company expects to have completed in mid-2015. Until this point, Udit Batra will run Merck Millipore and Rakesh Sachdev will run Sigma-Aldrich, and Mr Sachdev will serve in an advisory capacity to ensure a smooth transition.

Dr Batra has served as chief executive and president of Merck’s life science business Merck Millipore since March 2014, after joining the company in 2011 to head Merck’s group consumer health business.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK